|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL22 |
Gene summary for MRPL22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL22 | Gene ID | 29093 |
| Gene name | mitochondrial ribosomal protein L22 | |
| Gene Alias | HSPC158 | |
| Cytomap | 5q33.2 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q9NWU5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29093 | MRPL22 | C21 | Human | Oral cavity | OSCC | 1.92e-63 | 2.28e+00 | 0.2678 |
| 29093 | MRPL22 | C30 | Human | Oral cavity | OSCC | 3.15e-44 | 2.52e+00 | 0.3055 |
| 29093 | MRPL22 | C38 | Human | Oral cavity | OSCC | 3.44e-14 | 1.54e+00 | 0.172 |
| 29093 | MRPL22 | C43 | Human | Oral cavity | OSCC | 6.55e-56 | 1.04e+00 | 0.1704 |
| 29093 | MRPL22 | C46 | Human | Oral cavity | OSCC | 1.50e-39 | 9.98e-01 | 0.1673 |
| 29093 | MRPL22 | C51 | Human | Oral cavity | OSCC | 6.32e-15 | 1.13e+00 | 0.2674 |
| 29093 | MRPL22 | C57 | Human | Oral cavity | OSCC | 6.38e-22 | 9.22e-01 | 0.1679 |
| 29093 | MRPL22 | C06 | Human | Oral cavity | OSCC | 1.12e-10 | 1.60e+00 | 0.2699 |
| 29093 | MRPL22 | C07 | Human | Oral cavity | OSCC | 5.55e-06 | 1.40e+00 | 0.2491 |
| 29093 | MRPL22 | C08 | Human | Oral cavity | OSCC | 5.63e-48 | 1.08e+00 | 0.1919 |
| 29093 | MRPL22 | C09 | Human | Oral cavity | OSCC | 9.06e-06 | 3.86e-01 | 0.1431 |
| 29093 | MRPL22 | LN22 | Human | Oral cavity | OSCC | 6.25e-14 | 1.57e+00 | 0.1733 |
| 29093 | MRPL22 | LN46 | Human | Oral cavity | OSCC | 5.38e-18 | 9.68e-01 | 0.1666 |
| 29093 | MRPL22 | LP15 | Human | Oral cavity | LP | 2.78e-07 | 1.38e+00 | 0.2174 |
| 29093 | MRPL22 | LP17 | Human | Oral cavity | LP | 1.64e-06 | 1.19e+00 | 0.2349 |
| 29093 | MRPL22 | SYSMH2 | Human | Oral cavity | OSCC | 2.73e-31 | 1.22e+00 | 0.2326 |
| 29093 | MRPL22 | SYSMH3 | Human | Oral cavity | OSCC | 1.59e-32 | 1.12e+00 | 0.2442 |
| 29093 | MRPL22 | SYSMH4 | Human | Oral cavity | OSCC | 1.09e-03 | 1.87e-01 | 0.1226 |
| 29093 | MRPL22 | SYSMH6 | Human | Oral cavity | OSCC | 1.38e-07 | 5.03e-01 | 0.1275 |
| 29093 | MRPL22 | P4_S8_cSCC | Human | Skin | cSCC | 4.07e-11 | 1.23e-01 | -0.3095 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:004225512 | Liver | Cirrhotic | ribosome assembly | 39/4634 | 61/18723 | 1.07e-10 | 5.72e-09 | 39 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:004225522 | Liver | HCC | ribosome assembly | 50/7958 | 61/18723 | 2.79e-10 | 9.50e-09 | 50 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:004225520 | Oral cavity | OSCC | ribosome assembly | 49/7305 | 61/18723 | 4.73e-11 | 1.50e-09 | 49 |
| GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
| GO:0042254110 | Oral cavity | LP | ribosome biogenesis | 173/4623 | 299/18723 | 8.97e-35 | 1.41e-31 | 173 |
| GO:0042255110 | Oral cavity | LP | ribosome assembly | 44/4623 | 61/18723 | 8.20e-15 | 1.05e-12 | 44 |
| GO:002261329 | Skin | cSCC | ribonucleoprotein complex biogenesis | 302/4864 | 463/18723 | 5.13e-72 | 3.22e-68 | 302 |
| GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
| GO:004225529 | Skin | cSCC | ribosome assembly | 44/4864 | 61/18723 | 5.84e-14 | 3.81e-12 | 44 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL22 | SNV | Missense_Mutation | novel | c.223A>C | p.Lys75Gln | p.K75Q | Q9NWU5 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-OL-A66P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| MRPL22 | insertion | In_Frame_Ins | novel | c.494_495insCTTCCGAACAAGCCCAGTGCCTGC | p.Tyr165_Cys166insPheArgThrSerProValProAla | p.Y165_C166insFRTSPVPA | Q9NWU5 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| MRPL22 | SNV | Missense_Mutation | novel | c.172C>T | p.Pro58Ser | p.P58S | Q9NWU5 | protein_coding | deleterious(0.02) | benign(0.175) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| MRPL22 | SNV | Missense_Mutation | c.132N>C | p.Lys44Asn | p.K44N | Q9NWU5 | protein_coding | tolerated(0.17) | benign(0.005) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MRPL22 | SNV | Missense_Mutation | novel | c.231N>G | p.Ser77Arg | p.S77R | Q9NWU5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-MU-A8JM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL22 | SNV | Missense_Mutation | novel | c.161N>T | p.Pro54Leu | p.P54L | Q9NWU5 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| MRPL22 | insertion | Frame_Shift_Ins | novel | c.171_172insGAAATAT | p.Pro58GlufsTer22 | p.P58Efs*22 | Q9NWU5 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| MRPL22 | SNV | Missense_Mutation | rs763635105 | c.446N>A | p.Arg149His | p.R149H | Q9NWU5 | protein_coding | tolerated(0.11) | probably_damaging(0.967) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| MRPL22 | SNV | Missense_Mutation | c.593G>A | p.Arg198His | p.R198H | Q9NWU5 | protein_coding | tolerated(0.06) | possibly_damaging(0.773) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| MRPL22 | SNV | Missense_Mutation | rs200057403 | c.128G>A | p.Arg43Gln | p.R43Q | Q9NWU5 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-AJ-A8CV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |